Taylor D Robin, Jayaram Lata, Asher M Innes, Epton Michael J
Thoracic Society of Australia and New Zealand (New Zealand Branch).
N Z Med J. 2008 Nov 7;121(1285):106-18.
Although both inhaled corticosteroids and beta-agonists have been the mainstay of inhaled pharmacotherapy in the management of asthma for many years, as "preventers" and "relievers", the advent of combination inhalers has prompted a revision of how these drugs ought to be used in practice. Studies to investigate their role, not only as regular treatment but also "as required" for relief of breakthrough symptoms, have recently been reported. The results are prompting a paradigm shift as to how inhaler therapy should be prescribed. In this review, the Executive of the Thoracic Society of Australia and New Zealand (New Zealand Branch) provide recommendations on maintenance and relief strategies based on currently available evidence. It is recognised that with further data these recommendations may require revision after three years.
尽管多年来吸入性糖皮质激素和β受体激动剂一直是哮喘吸入药物治疗的主要手段，分别作为“预防药物”和“缓解药物”，但联合吸入器的出现促使人们重新审视这些药物在实际应用中的使用方式。最近有研究报告了它们的作用，不仅是作为常规治疗，还包括“按需”缓解突发症状。这些结果促使人们对吸入器治疗的处方方式进行范式转变。在本综述中，澳大利亚和新西兰胸科学会（新西兰分会）执行委员会根据现有证据就维持治疗和缓解策略提供了建议。人们认识到，随着更多数据的出现，这些建议可能在三年后需要修订。
